CAJ | 학술논문

目的探讨多药耐药(MDR)基因产物肺耐药蛋白(LRP)、DNA拓扑异构酶Ⅱ(TopoⅡ)在胆囊癌和胆管癌中的表达及其与耐药的关系.方法采用免疫组化的方法 (IHC)检测18例胆囊癌和36例胆管癌的上述两个指标的表达情况.结果在胆囊癌LRP、TopoⅡ的表达的阳性率分别为77.8%、83.3%,在胆管癌中表达的阳性率为75.0%和91.7%,显著高于对照组的23.1%和30.8%(P<0.05).除LRP、Topo Ⅱ的表达在胆管癌年龄>60岁组显著高于≤60岁组(P<0.05)之外,LRP、TopoⅡ与性别、年龄、病理分期、病理类型、分化程度、淋巴结转移无关(P>0.05).结论 LRP、TopoⅡ在未经化疗的胆囊癌和胆管癌组织中均有不同程度的高表达;胆囊癌和胆管癌的原发性多药耐药与LRP有关,应用TopoⅡ抑制剂治疗可能提高胆道癌的化疗效果.
목적 탐토다약내약(MDR)기인산물폐내약단백(LRP)、DNA탁복이구매Ⅱ(TopoⅡ)재담낭암화담관암중적표체급기여내약적관계.방법 채용면역조화적방법 (IHC)검측18례담낭암화36례담관암적상술량개지표적표체정황.결과 재담낭암LRP、TopoⅡ적표체적양성솔분별위77.8%、83.3%,재담관암중표체적양성솔위75.0%화91.7%,현저고우대조조적23.1%화30.8%(P<0.05).제LRP、Topo Ⅱ적표체재담관암년령>60세조현저고우≤60세조(P<0.05)지외,LRP、TopoⅡ여성별、년령、병리분기、병리류형、분화정도、림파결전이무관(P>0.05).결론 LRP、TopoⅡ재미경화료적담낭암화담관암조직중균유불동정도적고표체;담낭암화담관암적원발성다약내약여LRP유관,응용TopoⅡ억제제치료가능제고담도암적화료효과.
Objective To investigate the expression of LRP and Topo Ⅱ, products of MDR gene, in gallbladder carcinoma and cholangiocarcinoma and explore its relation to drug resistance. Methods The expression of LRP and TopoⅡ in gallbladder carcinoma and cholangiocarcinoma was determined with immunohistochemistry. Results The positive rate of expression of the 2 products was 77.8% and 83.3% in gallbladder carcinoma and 75.0% and 91.7% in cholangiocarcinoma, re-spectively. They were significantly higher than those of 23.1% and 30.8% in the control group (P< 0.05). Conclusion LRP and Topoll have high expression levels in gallbladder carcinoma and cholan-giocarcinoma before chemotherapy. The primary MDR of the 2 kinds of carcinoma might be associated with LRP. Using inhibiting agents of Topoll can promote the efficacy of chemotherapy for cholangio-carcinoma.